Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium

First Posted Date: 2014-06-24

Last Posted Date: 2014-11-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 441

Registration Number: NCT02172560

Locations: 🇦🇺
Boehringer Ingelheim Investigational Site 61503, Nedlands, Western Australia, Australia
🇦🇺
Boehringer Ingelheim Investigational Site 61405, Perth, Western Australia, Australia
🇦🇺
Boehringer Ingelheim Investigational Site 61502, Adelaide, South Australia, Australia

and more 16 locations

Bioavailability of BIBR 953 ZW in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 1048 low1
Drug: BIBR 1048 low2
Drug: BIBR 1048 medium
Drug: BIBR 1048 high
Drug: Pantoprazole

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT02170766

Bioavailability of Dabigatran and Amiodarone After Multiple Oral Administrations of Dabigatran Etexilate With or Without Amiodarone as Single Dose in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran etexilate
Drug: Amiodarone

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02171026

Bioavailability of BIBR 953 ZW After BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as Hydroxypropyl Methylcellulose (HPMC) Polymorph II Capsule Relative to HPMC Polymorph I Capsule in Healthy Subjects.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 1048 MS polymorph I
Drug: BIBR 1048 MS polymorph II

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT02170974

Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 1048 MS - low dose
Drug: BIBR 1048 MS + Pantoprazole
Drug: BIBR 1048 MS - high dose

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 26

Registration Number: NCT02170740

Bioavailability of BIBR 1048 MS With and Without Pantoprazole Under Influence of Food in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 1048 MS
Drug: Pantoprazole

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT02170610

Bioequivalence of Two Different Drug Product Batches of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran polymorph I (≈ 83%) and polymorph II (≈17%)
Drug: Dabigatran polymorph I

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 66

Registration Number: NCT02171013

Multiple Oral Doses of BIBR 1048 MS Solution in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 1048 MS low
Drug: BIBR 1048 MS medium 1
Drug: BIBR 1048 MS medium 2
Drug: BIBR 1048 MS high
Drug: BIBR 1048 MS placebo

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT02170831

Bioavailability of BIBR 953 ZW After Oral Administration of BIBR 1048 MS in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 1048 MS Capsule E
Drug: BIBR 1048 MS Capsule F
Drug: BIBR 1048 MS Capsule G
Drug: BIBR 1048 MS Tablet H
Drug: BIBR 1048 MS Drinking solution
Drug: Pantoprazole

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT02170636

Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo to BIBR 1048 MS
Drug: BIBR 1048 MS dose 1
Drug: BIBR 1048 MS dose 2
Drug: BIBR 1048 MS dose 3
Drug: BIBR 1048 MS dose 4
Drug: BIBR 1048 MS dose 5

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT02170116

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy